Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody
- PMID: 23618766
- PMCID: PMC4459498
- DOI: 10.1126/science.1234914
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody
Abstract
The prefusion state of respiratory syncytial virus (RSV) fusion (F) glycoprotein is the target of most RSV-neutralizing activity in human sera, but its metastability has hindered characterization. To overcome this obstacle, we identified prefusion-specific antibodies that were substantially more potent than the prophylactic antibody palivizumab. The cocrystal structure for one of these antibodies, D25, in complex with the F glycoprotein revealed D25 to lock F in its prefusion state by binding to a quaternary epitope at the trimer apex. Electron microscopy showed that two other antibodies, AM22 and 5C4, also bound to the newly identified site of vulnerability, which we named antigenic site Ø. These studies should enable design of improved vaccine antigens and define new targets for passive prevention of RSV-induced disease.
Figures




Similar articles
-
Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.J Virol. 2017 Jul 12;91(15):e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1. J Virol. 2017. PMID: 28539438 Free PMC article.
-
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9619-24. doi: 10.1073/pnas.1106536108. Epub 2011 May 17. Proc Natl Acad Sci U S A. 2011. PMID: 21586636 Free PMC article.
-
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6849-E6858. doi: 10.1073/pnas.1609449113. Epub 2016 Oct 17. Proc Natl Acad Sci U S A. 2016. PMID: 27791117 Free PMC article.
-
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.Curr Opin Virol. 2015 Apr;11:70-5. doi: 10.1016/j.coviro.2015.03.002. Epub 2015 Mar 26. Curr Opin Virol. 2015. PMID: 25819327 Free PMC article. Review.
-
Novel antigens for RSV vaccines.Curr Opin Immunol. 2015 Aug;35:30-8. doi: 10.1016/j.coi.2015.04.005. Epub 2015 Jun 10. Curr Opin Immunol. 2015. PMID: 26070108 Free PMC article. Review.
Cited by
-
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.J Virol. 2016 Jul 27;90(16):7508-7518. doi: 10.1128/JVI.00012-16. Print 2016 Aug 15. J Virol. 2016. PMID: 27279612 Free PMC article.
-
A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody.J Virol. 2021 May 10;95(11):e02279-20. doi: 10.1128/JVI.02279-20. Epub 2021 Mar 10. J Virol. 2021. PMID: 33692208 Free PMC article.
-
An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections.Nat Struct Mol Biol. 2019 Oct;26(10):980-987. doi: 10.1038/s41594-019-0308-9. Epub 2019 Sep 30. Nat Struct Mol Biol. 2019. PMID: 31570878 Free PMC article.
-
Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice.Front Immunol. 2022 Dec 12;13:1054005. doi: 10.3389/fimmu.2022.1054005. eCollection 2022. Front Immunol. 2022. PMID: 36578490 Free PMC article.
-
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein.Nat Commun. 2019 Sep 12;10(1):4153. doi: 10.1038/s41467-019-12137-1. Nat Commun. 2019. PMID: 31515478 Free PMC article.
References
-
- Glezen W, Taber L, Frank A, Kasel J. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986;140:543. - PubMed
-
- Shay DK, et al. Bronchiolitis-Associated Hospitalizations Among US Children, 1980–1996. JAMA. 1999;282:1440. - PubMed
-
- Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997;176:1215. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous